Nanomedicine for Depression: From Blood-Brain Barrier Delivery to Neuroimmune-Barrier-Plasticity Network...

Area of Science:

• Neuroscience and Nanotechnology
• Integrative review of brain disorder mechanisms and nanotherapeutic strategies

Background:

• Depression involves neuroinflammation, blood-brain barrier dysfunction, and impaired neuroplasticity within the neurovascular-glial-neuronal unit.
• Current nanotherapeutic strategies are diverse but require a disease-mechanism framework for optimization.

Purpose of the Study:

• To examine how engineered nanosystems can modulate depression-related neuroinflammation, barrier dysfunction, and neuroplasticity.
• To organize nanotherapeutic strategies based on disease mechanisms rather than material type.

Main Methods:

• Synthesized pathological nodes sustaining depression-related network dysfunction.
• Classified nanotherapeutic strategies into small-molecule delivery, nucleic acid carriers, and functional nanoplatforms.
• Focused on barrier navigation, targeting, stimulus-responsive release, and coordinated modulation of key pathological factors.

Main Results:

• Nanoplatforms require evaluation beyond brain accumulation, including patient stratification, target engagement, and safety.
• Identified translational bottlenecks such as patient selection, model relevance, neurotoxicity, and scalability.
• Proposed a precision nanomedicine framework guided by pathological networks.

Conclusions:

• A disease-mechanism-centered approach is crucial for advancing nanomedicine for depression.
• Future nanomedicine development should focus on precision network-oriented interventions.
• Integrating biomarkers and human-relevant models will guide clinical translation.